 | Up a level |
Number of items: 1.
Ratner, E. S., Keane, F. K., Lindner, R., Tassi, R. A., Paranjape, T., Glasgow, M., Nallur, S., Deng, Y., Lu, L., Steele, L., Sand, S., Muller, R-U, Bignotti, E., Bellone, S., Boeke, M., Yao, X., Pecorelli, S., Ravaggi, A., Katsaros, D., Zelterman, D., Cristea, M. C., Yu, H., Rutherford, T. J., Weitzel, J. N., Neuhausen, S. L., Schwartz, P. E., Slack, F. J., Santin, A. D. and Weidhaas, J. B. (2012). A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene, 31 (42). S. 4559 - 4567. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5594